Precision Business Insights
Portfolio

 

Research Reports

Pulmonary Embolism Treatment Market: Global Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Pulmonary Embolism Treatment Market: By drug class (Anticoagulant, Thrombolytics), By route of administration (Oral, Intravenous, Subcutaneous), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013 to 2017 and Forecast 2018 to 2024

Global Pulmonary Embolism Treatment market was valued at US $ XX Mn and expected to grow at XX% Compound Annual Growth Rate (CAGR) over the 2018 to 2024

 

Market Outline: Pulmonary Embolism Treatment Market

Pulmonary embolism is a blockage in pulmonary arteries in lungs. The cause of blockage is usually a blood clot. The clots are observed to be small and are not harmful, but they can damage the lungs due to restricted blood flow, decrease oxygen levels in the blood, and affect other organs as well. As the clot blocks the blood flow to the lungs, pulmonary embolism can be life-threatening. However, prompt treatment could save your life or reduce the risk of future problems. The major aim of treatment is to break up clots and avoid the formation of clots. Pulmonary embolism (PE) is treated with medicines, procedures, and other therapies.

Market Dynamics: Pulmonary Embolism Treatment Market

Increase in the incidence of cancer, surge in cardiac disorders are expected to increases the pulmonary embolism. The growth in the number of cancer patients is expected to increase the revenue share of the market. Rise in the aging population, increasing obesity problems enable fuel the growth of pulmonary embolism treatment market. However, introduction of novel oral anticoagulants and the high cost for the treatment are expected to hamper the growth of pulmonary embolism treatment market.

Market Scope: Pulmonary Embolism Treatment Market

Pulmonary Embolism Treatment market is segmented based on the drug class, route of administration, and distribution channel

Based on the drug class, the market is segmented into the following:

  • Anticoagulant
    • Warfarin
    • Heparin
    • Low molecular-weight heparin
    • Fondaparinux (Arixtra)
    • Other
  • Thrombolytics
    • Reteplase
    • Alteplase
    • Others

Based on the route of administration, the market is segmented into the following:

  • Oral
  • Intravenous
  • Subcutaneous

Based on the distribution channel, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Analysis:  Pulmonary Embolism Treatment Market

Geographically, global pulmonary embolism treatment market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America dominated the pulmonary embolism treatment market due to high medical reimbursement facilities, and technological advancements. However, Asia Pacific pulmonary embolism treatment market is forecasted to have the fastest growth, owing to a rapidly increasing population, rise in patient awareness, favorable government policies, and modernization of healthcare infrastructure. The growth in the medical tourism industry is expected to boost the growth of pulmonary embolism treatment market in the Asia Pacific region.

Competition Assessment: Pulmonary Embolism Treatment Market

Some of the key players of pulmonary embolism market pipeline therapeutics include:

  • Accu-Break Pharmaceuticals Inc (U.S)
  • Daiichi Sankyo Company Ltd (Japan)
  • Dong-A Socio Holdings Co Ltd (South Korea)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Genentech Inc (U.S)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Verseon Corp (U.S)

Notable Market Developments: Pulmonary Embolism Treatment Market

  • In November 2012, Janssen Pharmaceuticals, Inc. (Janssen) announced the U.S. Food and Drug Administration (FDA) has approved XARELTO (rivaroxaban), an oral anticoagulant, for the treatment of deep vein thrombosis (DVT) and/or pulmonary embolism (PE), and to reduce the risk of recurrence of DVT and PE following initial treatment

 

Key Features of the Report:

  • The report covers exhaustive regional information, that includes North America (the USA and Canada), Europe (Germany, France, Italy, UK, Spain, Russia, Poland and Rest of Europe), Asia-Pacific (Japan, China, India, Australia & New Zealand, ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others), South Korea, and Rest of Asia-Pacific), Latin America (Brazil, Mexico, Argentian, Venezula, and Rest of Latin America), and Middle East and Africa (Gulf Cooperation Council (GCC) Countries, Israel, South Africa, and Rest of Middle East and Africa)
  • The report provides granular level information about the market size, regional market share, historic market (2013-2017) and forecast (2018-2024)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments and startup’s details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework and reimbursement scenario
  • The report analyses the impact of the socio-political environment through PESTLE Analysis and competition through Porter’s Five Force Analysis in addition to recent technology advancements and innovations in the market
  • Accu-Break Pharmaceuticals Inc (U.S)
  • Daiichi Sankyo Company Ltd (Japan)
  • Dong-A Socio Holdings Co Ltd (South Korea)
  • Hoffmann-La Roche Ltd (Switzerland)
  • Genentech Inc (U.S)
  • Janssen Pharmaceuticals, Inc (Belgium)
  • Verseon Corp (U.S)

A complementary 2hrs free facility through which report buyers can interact with our pool of experienced analysts for any report related queries, clarifications or additional data requirements

 

Contact SalesTOLL FREE: +1-866-598-1553